Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder | Zendy

Sean J. Pittock | Zendy; Achim Berthele | Zendy; Kazuo Fujihara | Zendy; Ho Jin Kim | Zendy; Michael Levy | Zendy; Jacqueline Palace | Zendy; Ichiro Nakashima | Zendy; Murat Terzi | Zendy; N. А. Totolyan | Zendy; Shanthi Viswanathan | Zendy; Kaichen Wang | Zendy; Amy Pace | Zendy; Kenji P. Fujita | Zendy; Róisín Armstrong | Zendy; Dean M. Wingerchuk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

Author(s) -

Sean J. Pittock,

Achim Berthele,

Kazuo Fujihara,

Ho Jin Kim,

Michael Levy,

Jacqueline Palace,

Ichiro Nakashima,

Murat Terzi,

N. А. Totolyan,

Shanthi Viswanathan,

Kaichen Wang,

Amy Pace,

Kenji P. Fujita,

Róisín Armstrong,

Dean M. Wingerchuk

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1900866

Subject(s) - neuromyelitis optica , eculizumab , spectrum disorder , aquaporin 4 , medicine , aquaporin , immunology , pathology , antibody , psychiatry , complement system , physiology

Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord. At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage to the central nervous system. In a previous small, open-label study involving patients with AQP4-IgG-positive disease, eculizumab, a terminal complement inhibitor, was shown to reduce the frequency of relapse.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research